Calypso taps Vertatschitsch as CEO

Clint vanSonnenberg | | Health Imaging | Artificial Intelligence
Calypso Medical Technologies has named Edward Vertatschitsch, PhD, as the company's president and CEO.

Vertatschitsch, who has served as executive vice president of operations as well as research and development, and is currently interim CEO, has worked with Calypso for seven years. Previously, Vertatschitsch managed hardware development at Palm, where he managed the development of the PDA, after serving as chief scientist at Boeing.

Vertatschitsch earned his PhD in electrical engineering from McMaster University in Ontario. Calypso develops real-time localization technology for tumor-tracking and is headquartered in Seattle.

Clint vanSonnenberg

Related Content

Commercially available AI increases breast cancer detection by nearly 20%
Clinicians want AI to show its work
ACR Assess-AI national data registry tracks performance of clinical algorithms
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA
PHOTO GALLERY: Medical imaging technology at RSNA 2024
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.